GENinCode Plc announced the presentation by Kaiser Permanente, US on the ' Utility of the CARDIO inCode-Score®? CHD polygenic risk score for incident coronary heart disease interplay with lifestyle in a multi-ethnic cohort of more than 60,000 individuals'. The presentation was made at the Annual Meeting of the European Society of Cardiologists Congress over 25-28 August 2023 in Amsterdam.

The study investigated over 60,000 adult individuals with no history of Coronary Heart Disease (CHD) from the Genetic Epidemiology Resource in Adult Health and Aging (GERA) multi-ethnic cohort of the Kaiser Permanente Medical Care plan of Northern California, USA. The GERA cohort followed the membership over an average of 14 years, using CARDIO inCode-Score to assess the polygenic risk of CHD, interplay with lifestyle and the incidence of CHD. Other recently announced news As previously announced, GENinCode is commencing Early Access Programs for CIC-SCORE (or CARDIO inCode- Score®?) with leading healthcare institutions in the United States to provide an improved estimation of an individual's risk of heart attack over their lifetime.

CIC-Score is now being commercially delivered from the GENinCode CLIA and CAP approved laboratory in Irvine, California. As also announced, the Company has recently filed its CIC-Score pre-market notifification (510k) medical device filing with the FDA. The Company expects to receive FDA approval for the CIC-SCORE medical device over the next 6 months enabling scale up and processing by CLIA labs across the United States.

In the UK around 7.6m people live with heart and circulatory disease, which causes 25% of all deaths annually. CVD can be reduced by identifying and treating individuals at risk, and the NHS 10 Year Plan (2019) sets out to address CVD prevention.